Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD

[1]  S. Yong,et al.  Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study , 2020, International journal of chronic obstructive pulmonary disease.

[2]  Yuejun Du,et al.  Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. , 2019, International immunopharmacology.

[3]  J. Yim,et al.  Risk for pneumonia requiring hospitalization or emergency room visit according to delivery device for inhaled corticosteroid/long-acting beta-agonist in patients with chronic airway diseases as real-world evidence , 2019, Scientific Reports.

[4]  S. Suissa,et al.  Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. , 2019, Chest.

[5]  Seon-Sook Han,et al.  Inhaled Corticosteroid-Related Tuberculosis in the Real World Among Patients with Asthma and COPD: A 10-Year Nationwide Population-Based Study. , 2019, The journal of allergy and clinical immunology. In practice.

[6]  Meilan K. Han,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.

[7]  Pengfei Guo,et al.  A meta-analysis of randomized controlled trials , 2019, Medicine.

[8]  S. Suissa,et al.  Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. , 2018, The Lancet. Respiratory medicine.

[9]  A. Anzueto,et al.  Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial , 2018, Respiratory Research.

[10]  C. Strange,et al.  Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? , 2018, International journal of chronic obstructive pulmonary disease.

[11]  A. Anzueto,et al.  The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. , 2018, The American journal of medicine.

[12]  B. Nordestgaard,et al.  Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD , 2018, European Respiratory Journal.

[13]  Meilan K. Han,et al.  Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD , 2018, The New England journal of medicine.

[14]  C. Janson,et al.  Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD , 2017, International journal of chronic obstructive pulmonary disease.

[15]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary , 2017, European Respiratory Journal.

[16]  J. Wedzicha,et al.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. , 2017, American journal of respiratory and critical care medicine.

[17]  B. Nordestgaard,et al.  Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.

[18]  D. Caillaud,et al.  Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? , 2014, European Respiratory Journal.

[19]  C. Janson,et al.  Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) , 2013, BMJ.

[20]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[21]  Bernadette A. Thomas,et al.  Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[22]  T. Seemungal,et al.  Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.

[23]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[24]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[25]  Eaton Rp.  Portable insulin infusion pumps: what is their role in therapy? , 1982 .

[26]  J. Wardle,et al.  Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.

[27]  T. Lasserson,et al.  Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.